1
|
Rekowski SP, Wani AA, Conrad J, Bharatam PV, Frey W, Beifuss U. Transition metal-free diastereospecific synthesis of (Z)-2-arylidene-2,3-dihydrobenzo[b][1,4]dioxines by reaction of (Z)-1,2-dibromo-3-aryl-2-propenes with catechols. Tetrahedron 2020. [DOI: 10.1016/j.tet.2020.131482] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Miao N, Jin J, Kim SN, Sun T. Hippocampal MicroRNAs Respond to Administration of Antidepressant Fluoxetine in Adult Mice. Int J Mol Sci 2018; 19:ijms19030671. [PMID: 29495532 PMCID: PMC5877532 DOI: 10.3390/ijms19030671] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 02/23/2018] [Accepted: 02/24/2018] [Indexed: 12/13/2022] Open
Abstract
Current antidepressant treatments to anxiety and depression remain inadequate, burdened by a significant percentage of misuse and drug side-effects, due to unclear mechanisms of actions of antidepressants. To better understand the regulatory roles of antidepressant fluoxetine-related drug reactions, we here investigate changes of expression levels of hippocampal microRNAs (miRNAs) after administration of fluoxetine in normal adult mice. We find that 64 miRNAs showed significant changes between fluoxetine treatment and control groups by analyzing 626 mouse miRNAs. Many miRNAs in response to fluoxetine are involved in neural-related signaling pathways by analyzing miRNA-target gene pairs using the Kyoto encyclopedia of genes and genomes (KEGG) and Gene Ontology (GO). Moreover, miRNAs with altered expression are mainly associated with the repression of the dopaminergic synapse signals, which may affect hippocampal function after fluoxetine treatment. Our results demonstrate that a number of miRNAs respond to antidepressants even in normal mice and may affect target gene expression, which supports the safety consideration of inappropriate treatment and off-label use of antidepressant drugs.
Collapse
Affiliation(s)
- Nan Miao
- Center for Precision Medicine, School of Medicine and School of Biomedical Sciences, Huaqiao University, 668 Jimei Road, Xiamen 361021, China.
| | - Junghee Jin
- Department of Cell and Developmental Biology, Cornell University Weill Medical College, 1300 York Avenue, Box 60, New York, NY 10065, USA.
| | - Seung-Nam Kim
- Department of Cell and Developmental Biology, Cornell University Weill Medical College, 1300 York Avenue, Box 60, New York, NY 10065, USA.
- College of Korean Medicine, Dongguk University, Ilsandonggu, Goyangsi 10326, Gyeonggido, Korea.
| | - Tao Sun
- Center for Precision Medicine, School of Medicine and School of Biomedical Sciences, Huaqiao University, 668 Jimei Road, Xiamen 361021, China.
- Department of Cell and Developmental Biology, Cornell University Weill Medical College, 1300 York Avenue, Box 60, New York, NY 10065, USA.
| |
Collapse
|
3
|
Baranov DS, Gatilov YV. Cyclization of 2-(3-R-prop-2-ynyloxy)-4-phenyliminonaphthalen- 1(4H)-ones into 2-R-methylidene-6-phenylamino-2,3-dihydronaphtho[2,1-b]-1,4-dioxines. MENDELEEV COMMUNICATIONS 2016. [DOI: 10.1016/j.mencom.2016.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
4
|
Kumar B, Sheetal S, Mantha AK, Kumar V. Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders. RSC Adv 2016. [DOI: 10.1039/c6ra00302h] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Development of MAO inhibitors as effective drug candidates for the management and/or treatment of different neurological disorders.
Collapse
Affiliation(s)
- Bhupinder Kumar
- Laboratory of Organic and Medicinal Chemistry
- Centre for Pharmaceutical Sciences and Natural Products
- Central University of Punjab
- Bathinda
- India-151001
| | - Sheetal Sheetal
- Laboratory of Organic and Medicinal Chemistry
- Centre for Pharmaceutical Sciences and Natural Products
- Central University of Punjab
- Bathinda
- India-151001
| | - Anil K. Mantha
- Centre for Animal Sciences
- School of Basic and Applied Sciences
- Central University of Punjab
- Bathinda
- India
| | - Vinod Kumar
- Laboratory of Organic and Medicinal Chemistry
- Centre for Pharmaceutical Sciences and Natural Products
- Central University of Punjab
- Bathinda
- India-151001
| |
Collapse
|
5
|
A mild and practical procedure for synthesis of substituted 2-aminobenzophenones. RESEARCH ON CHEMICAL INTERMEDIATES 2015. [DOI: 10.1007/s11164-014-1751-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
6
|
Dhar AK, Mahesh R, Jindal A, Bhatt S. Piperazine Analogs of Naphthyridine-3-carboxamides and Indole-2-carboxamides: Novel 5-HT3Receptor Antagonists with Antidepressant-Like Activity. Arch Pharm (Weinheim) 2015; 348:34-45. [DOI: 10.1002/ardp.201400293] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2014] [Revised: 10/05/2014] [Accepted: 10/17/2014] [Indexed: 11/06/2022]
Affiliation(s)
- Arghya K. Dhar
- Department of Pharmacy; FD-III; Birla Institute of Technology & Science; Pilani Rajasthan India
| | - Radhakrishnan Mahesh
- Department of Pharmacy; FD-III; Birla Institute of Technology & Science; Pilani Rajasthan India
| | - Ankur Jindal
- School of Medicine; University of New Mexico; Albuquerque USA
| | - Shvetank Bhatt
- Department of Pharmacy; FD-III; Birla Institute of Technology & Science; Pilani Rajasthan India
| |
Collapse
|
7
|
Dhar AK, Mahesh R, Jindal A, Devadoss T, Bhatt S. Design, Synthesis, and Pharmacological Evaluation of Novel 2-(4-substituted piperazin-1-yl)1, 8 Naphthyridine 3-Carboxylic Acids as 5-HT3Receptor Antagonists for the Management of Depression. Chem Biol Drug Des 2014; 84:721-31. [DOI: 10.1111/cbdd.12370] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Revised: 04/13/2014] [Accepted: 05/22/2014] [Indexed: 11/29/2022]
Affiliation(s)
- Arghya K. Dhar
- Department of Pharmacy; FD-III, Birla Institute of Technology & Science; Pilani Rajasthan 333 031 India
| | - Radhakrishnan Mahesh
- Department of Pharmacy; FD-III, Birla Institute of Technology & Science; Pilani Rajasthan 333 031 India
| | - Ankur Jindal
- Department of Pharmacy; FD-III, Birla Institute of Technology & Science; Pilani Rajasthan 333 031 India
| | - Thangaraj Devadoss
- Department of Pharmacy; FD-III, Birla Institute of Technology & Science; Pilani Rajasthan 333 031 India
| | - Shvetank Bhatt
- Department of Pharmacy; FD-III, Birla Institute of Technology & Science; Pilani Rajasthan 333 031 India
| |
Collapse
|
8
|
Mahesh R, Dhar AK, Jindal A, Bhatt S. Design, Synthesis and Evaluation of Antidepressant Activity of Novel 2-Methoxy 1, 8 Naphthyridine 3-Carboxamides as 5-HT3Receptor Antagonists. Chem Biol Drug Des 2014; 83:583-91. [DOI: 10.1111/cbdd.12271] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Revised: 09/23/2013] [Accepted: 11/25/2013] [Indexed: 01/16/2023]
Affiliation(s)
- Radhakrishnan Mahesh
- Department of Pharmacy; FD-III; Birla Institute of Technology & Science; Pilani Rajasthan 333 031 India
| | - Arghya Kusum Dhar
- Department of Pharmacy; FD-III; Birla Institute of Technology & Science; Pilani Rajasthan 333 031 India
| | - Ankur Jindal
- Department of Pharmacy; FD-III; Birla Institute of Technology & Science; Pilani Rajasthan 333 031 India
| | - Shvetank Bhatt
- Department of Pharmacy; FD-III; Birla Institute of Technology & Science; Pilani Rajasthan 333 031 India
| |
Collapse
|
9
|
Chen HX, Jin ZL, Zhang LM, Xue R, Xu XD, Zhao N, Qiu ZK, Wang XW, Zhang YZ, Yang RF, Li YF. Antidepressant-like activity of YL-0919: a novel combined selective serotonin reuptake inhibitor and 5-HT1A receptor agonist. PLoS One 2013; 8:e83271. [PMID: 24367588 PMCID: PMC3867442 DOI: 10.1371/journal.pone.0083271] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2013] [Accepted: 11/10/2013] [Indexed: 11/19/2022] Open
Abstract
It has been suggested that drugs combining activities of selective serotonin reuptake inhibitor and 5-HT1A receptor agonist may form a novel strategy for higher therapeutic efficacy of antidepressant. The present study aimed to examine the pharmacology of YL-0919, a novel synthetic compound with combined high affinity and selectivity for serotonin transporter and 5-HT1A receptors. We performed in vitro binding and function assays and in vivo behavioral tests to assess the pharmacological properties and antidepressant-like efficacy of YL-0919. YL-0919 displayed high affinity in vitro to both 5-HT1A receptor and 5-HT transporter prepared from rat cortical tissue. It exerted an inhibitory effect on forskolin-stimulated cAMP formation and potently inhibited 5-HT uptake in both rat cortical synaptosomes and recombinant cells. After acute p.o. administration, very low doses of YL-0919 reduced the immobility time in tail suspension test and forced swimming test in mice and rats, with no significant effect on locomotor activity in open field test. Furthermore, WAY-100635 (a selective 5-HT1A receptor antagonist, 0.3 mg/kg) significantly blocked the effect of YL-0919 in tail suspension test and forced swimming test. In addition, chronic YL-0919 treatment significantly reversed the depressive-like behaviors in chronically stressed rats. These findings suggest that YL-0919, a novel structure compound, exerts dual effect on the serotonergic system, as both 5-HT1A receptor agonist and 5-HT uptake blocker, showing remarkable antidepressant effects in animal models. Therefore, YL-0919 may be used as a new option for the treatment of major depressive disorder.
Collapse
Affiliation(s)
- Hong-xia Chen
- Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
| | - Zeng-liang Jin
- Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
- Department of Pharmacology, School of Basic Medical Scieneces, Capital Medical University, Beijing, P. R. of China
| | - Li-ming Zhang
- Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
| | - Rui Xue
- Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
| | - Xiao-dan Xu
- Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
| | - Nan Zhao
- Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
| | - Zhi-kun Qiu
- Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
| | - Xian-wang Wang
- Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
- Department of Anesthesiology, Chinese PLA 309 Hospital, Beijing, P. R. of China
| | - You-zhi Zhang
- Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
| | - Ri-fang Yang
- Department of Medicinal Chemistry, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
| | - Yun-feng Li
- Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. of China
| |
Collapse
|
10
|
Castillo JC, Abonía R, Cobo J, Glidewell C. Dibenzylammonium hydrogen maleate and a redetermination at 120 K of bis(dibenzylamino)methane. Acta Crystallogr C 2013; 69:798-802. [DOI: 10.1107/s010827011301651x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2013] [Accepted: 06/13/2013] [Indexed: 11/10/2022] Open
Abstract
In dibenzylammonium hydrogen maleate [or dibenzylammonium (2Z)-3-carboxyprop-2-enoate], C14H16N+·C4H3O4−, (I), the anion contains a fairly short and nearly linear O—H...O hydrogen bond, with an O...·O distance of 2.4603 (16) Å, but with the H atom clearly offset from the mid-point of the O...O vector. The counter-ions in (I) are linked by two N—H...O hydrogen bonds to formC22(6) chains and these chains are weakly linked into sheets by a C—H...O hydrogen bond. Bis(dibenzylamino)methane, C29H30N2, (II), crystallizes with two independent molecules lying across twofold rotation axes in the space groupC2/c, and the molecules are conformationally chiral; there are no direction-specific intermolecular interactions in the crystal structure of (II).
Collapse
|
11
|
Abonia R, Castillo J, Insuasty B, Quiroga J, Nogueras M, Cobo J. Efficient catalyst-free four-component synthesis of novel γ-aminoethers mediated by a Mannich type reaction. ACS COMBINATORIAL SCIENCE 2013; 15:2-9. [PMID: 23167924 DOI: 10.1021/co300105t] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Herein, it is provided an efficient and one-pot procedure for the synthesis of novel and diversely substituted γ-aminoethers in good yields through a four-component process by treatment of benzylamines with polyformaldehyde and activated alkenes in aliphatic alcohols acting both as solvent and as etherificant agents. Reactions proceeded via a Mannich-type reaction, where the formation of iminium ions and aminals was identified as the key intermediates to obtain the target products.
Collapse
Affiliation(s)
- Rodrigo Abonia
- Research Group of Heterocyclic
Compounds, Department of Chemistry, Universidad del Valle, A. A. 25360, Cali, Colombia
| | - Juan Castillo
- Research Group of Heterocyclic
Compounds, Department of Chemistry, Universidad del Valle, A. A. 25360, Cali, Colombia
| | - Braulio Insuasty
- Research Group of Heterocyclic
Compounds, Department of Chemistry, Universidad del Valle, A. A. 25360, Cali, Colombia
| | - Jairo Quiroga
- Research Group of Heterocyclic
Compounds, Department of Chemistry, Universidad del Valle, A. A. 25360, Cali, Colombia
| | - Manuel Nogueras
- Department of Inorganic and
Organic Chemistry, Universidad de Jaén, 23071 Jaén, Spain
| | - Justo Cobo
- Department of Inorganic and
Organic Chemistry, Universidad de Jaén, 23071 Jaén, Spain
| |
Collapse
|
12
|
Zhang XM, Qiu M, Sun J, Zhang YB, Yang YS, Wang XL, Tang JF, Zhu HL. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents. Bioorg Med Chem 2011; 19:6518-24. [PMID: 21962523 DOI: 10.1016/j.bmc.2011.08.013] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2011] [Revised: 08/07/2011] [Accepted: 08/08/2011] [Indexed: 11/24/2022]
Abstract
In present study, a series of new 1,3,4-oxadiazole derivatives containing 1,4-benzodioxan moiety (6a-6s) as potential telomerase inhibitors were synthesized. The bioassay tests demonstrated that compounds 6k, 6l, 6m, 6n and 6s exhibited broad-spectrum antitumor activity with IC(50) concentration range from 7.21 μM to 25.87 μM against the four cancer cell lines, HEPG2, HELA, SW1116 and BGC823. Moreover, all the title compounds were assayed for telomerase inhibition using the TRAP-PCR-ELISA assay. The results showed compound 6k possessed the most potent telomerase activity (IC(50)=1.27 ± 0.05 μM). Docking simulation was performed to position compound 6k into the active site of telomerase (3DU6) to determine the probable binding model.
Collapse
Affiliation(s)
- Xiao-Min Zhang
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, People's Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Gopishetty B, Gogoi S, Dutta A. An improved asymmetric synthetic route to a novel triple uptake inhibitor antidepressant (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol (D-142). ACTA ACUST UNITED AC 2011; 22:1081-1086. [PMID: 21927543 DOI: 10.1016/j.tetasy.2011.05.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Triple monoamine reuptake inhibitors have been implicated in the development of a new generation of antidepressants with higher efficacy than the currently existing therapies. In this paper, we have developed an alternative efficient synthetic route for triple monoamine reuptake inhibitor D-142 in 18.5% overall yield in 11 steps starting from diphenylmethane. D-142 was developed by us recently. The key step of the present synthetic strategy is the preferential formation of a bromohydrin from olefin via a cis-bromoinum intermediate, which introduced significant efficiency in the overall synthesis. Furthermore, we have developed an efficient way to recycle the optically active intermediate diol back to the desired chiral epoxide.
Collapse
Affiliation(s)
- Bhaskar Gopishetty
- Wayne State University, Department of Pharmaceutical Sciences, Detroit, MI 48202, USA
| | | | | |
Collapse
|
14
|
Discovery of new anti-depressants from structurally novel 5-HT3 receptor antagonists: Design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides. Bioorg Med Chem Lett 2011; 21:1253-6. [DOI: 10.1016/j.bmcl.2010.12.064] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2010] [Revised: 12/13/2010] [Accepted: 12/15/2010] [Indexed: 11/22/2022]
|
15
|
Mahesh R, Devadoss T, Pandey DK, Bhatt S, Yadav SK. Design, synthesis and structure–activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression. Bioorg Med Chem Lett 2010; 20:6773-6. [DOI: 10.1016/j.bmcl.2010.08.128] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2010] [Revised: 08/05/2010] [Accepted: 08/27/2010] [Indexed: 10/19/2022]
|
16
|
Nyola A, Karpowich NK, Zhen J, Marden J, Reith ME, Wang DN. Substrate and drug binding sites in LeuT. Curr Opin Struct Biol 2010; 20:415-22. [PMID: 20739005 DOI: 10.1016/j.sbi.2010.05.007] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2010] [Revised: 05/14/2010] [Accepted: 05/20/2010] [Indexed: 01/13/2023]
Abstract
LeuT is a member of the neurotransmitter/sodium symporter family, which includes the neuronal transporters for serotonin, norepinephrine, and dopamine. The original crystal structure of LeuT shows a primary leucine-binding site at the center of the protein. LeuT is inhibited by different classes of antidepressants that act as potent inhibitors of the serotonin transporter. The newly determined crystal structures of LeuT-antidepressant complexes provide opportunities to probe drug binding in the serotonin transporter, of which the exact position remains controversial. Structure of a LeuT-tryptophan complex shows an overlapping binding site with the primary substrate site. A secondary substrate binding site was recently identified, where the binding of a leucine triggers the cytoplasmic release of the primary substrate. This two binding site model presents opportunities for a better understanding of drug binding and the mechanism of inhibition for mammalian transporters.
Collapse
Affiliation(s)
- Ajeeta Nyola
- Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular Medicine, and Department of Cell Biology, New York University School of Medicine, 540 First Avenue, New York, NY 10016, USA
| | | | | | | | | | | |
Collapse
|
17
|
Lv PC, Wang KR, Mao WJ, Xiong J, Li HQ, Yang Y, Shi L, Zhu HL. Synthesis, Crystal Structure and Immunosuppressive Activity of Acylamide Derivatives Containing 1,4-Benzodioxan. ChemMedChem 2009; 4:1421-4. [DOI: 10.1002/cmdc.200900167] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
18
|
Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol 2009; 16:652-7. [PMID: 19430461 DOI: 10.1038/nsmb.1602] [Citation(s) in RCA: 191] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2009] [Accepted: 04/07/2009] [Indexed: 11/08/2022]
Abstract
Sertraline and fluoxetine are selective serotonin re-uptake inhibitors (SSRIs) that are widely prescribed to treat depression. They exert their effects by inhibiting the presynaptic plasma membrane serotonin transporter (SERT). All SSRIs possess halogen atoms at specific positions, which are key determinants for the drugs' specificity for SERT. For the SERT protein, however, the structural basis of its specificity for SSRIs is poorly understood. Here we report the crystal structures of LeuT, a bacterial SERT homolog, in complex with sertraline, R-fluoxetine or S-fluoxetine. The SSRI halogens all bind to exactly the same pocket within LeuT. Mutation at this halogen-binding pocket (HBP) in SERT markedly reduces the transporter's affinity for SSRIs but not for tricyclic antidepressants. Conversely, when the only nonconserved HBP residue in both norepinephrine and dopamine transporters is mutated into that found in SERT, their affinities for all the three SSRIs increase uniformly. Thus, the specificity of SERT for SSRIs is dependent largely on interaction of the drug halogens with the protein's HBP.
Collapse
|
19
|
Bao W, Liu Y, Lv X, Qian W. Cu2O-Catalyzed Tandem Ring-Opening/Coupling Cyclization Process for the Synthesis of 2,3-Dihydro-1,4-benzodioxins. Org Lett 2008; 10:3899-902. [DOI: 10.1021/ol801444p] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Weiliang Bao
- Department of Chemistry, Zhejiang University, Xi Xi Campus, Hangzhou, Zhejiang 310028, P. R. of China
| | - Yunyun Liu
- Department of Chemistry, Zhejiang University, Xi Xi Campus, Hangzhou, Zhejiang 310028, P. R. of China
| | - Xin Lv
- Department of Chemistry, Zhejiang University, Xi Xi Campus, Hangzhou, Zhejiang 310028, P. R. of China
| | - Weixing Qian
- Department of Chemistry, Zhejiang University, Xi Xi Campus, Hangzhou, Zhejiang 310028, P. R. of China
| |
Collapse
|
20
|
Becker I. Preparation of derivatives of 1-(2-pyrimidinyl)piperazine as potential antianxiety, antidepressant, and antipsychotic agents. J Heterocycl Chem 2008. [DOI: 10.1002/jhet.5570450410] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
21
|
D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action. Eur J Pharmacol 2008; 589:73-9. [PMID: 18561912 DOI: 10.1016/j.ejphar.2008.05.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2007] [Revised: 04/21/2008] [Accepted: 05/13/2008] [Indexed: 11/24/2022]
Abstract
Deficiency in dopaminergic activity has been linked to a depressed state in pharmacological and clinical studies. Current pharmacological treatment for depression primarily involves modulation of serotonergic and noradrenergic systems but not dopaminergic neurotransmission. Available pharmacotherapy for depression has a number of drawbacks as a significant number of people are either refractory or develop tolerance to the antidepressant agents resulting in relapse. Furthermore, the slow onset of action of current therapies often poses a challenge for effective treatment. In our effort to develop novel molecules impacting all three above mentioned monoamine systems, we discovered structurally unique pyran derivatives with various profiles in inhibiting monoamine transporters. One of our lead molecules, D-161 exhibited triple monoamine transporter inhibitory activity with the highest affinity for norepinephrine transporter (NET) followed by its affinity for serotonin transporter (SERT) and dopamine transporter (DAT). D-161 exhibited potent activity in reducing immobility significantly in the rat forced swim test as well as in the mouse tail suspension test. Moreover, results from locomotor activity tests indicated that the reduction of immobility by D-161 was not due to motor activation as no significant motor activation was observed when the rats were subjected to the same doses of drug under the same conditions as in the forced swim test. These results suggest that the novel asymmetric pyran derivative D-161 with unique molecular structure exhibiting triple monoamine transporter inhibitory activity could possess potent antidepressant activity.
Collapse
|
22
|
Williams M. The Decade of the Brain Initiative and Health Care Reform: Irreconcilable Differences? Expert Opin Investig Drugs 2008. [DOI: 10.1517/13543784.3.9.947] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
23
|
Perrone R, Berardi F, Colabufo NA, Lacivita E, Larizza C, Leopoldo M, Tortorella V. Design and synthesis of long-chain arylpiperazines with mixed affinity for serotonin transporter (SERT) and 5-HT(1A) receptor. J Pharm Pharmacol 2006; 57:1319-27. [PMID: 16259761 DOI: 10.1211/jpp.57.10.0011] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
A new generation of antidepressant agents could be represented by compounds with mixed activity as serotonin transporter (SERT) inhibitors and 5-HT(1A) receptor antagonists. We report here on the synthesis and evaluation of SERT and 5-HT(1A) receptor affinity of long-chain arylpiperazines obtained either by modifying 6-nitroquipazine into a long-chain arylpiperazine or by inserting a modified 6-nitroquipazine moiety or other structures endowed with SERT affinity into a long-chain arylpiperazine with 5-HT(1A) affinity. Among the compounds studied, 2-[4-(2-methoxyphenyl)piperazin-1-yl]-N-(6-nitro-2-quinolyl)ethylamine (21) and 1-(5-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)-3-[4-(2-methoxyphenyl)-piperazin-1-yl]-1-propanone (24) showed good affinity values for SERT and 5-HT(1A) receptors (SERT: K(i) (inhibition constant)=71.8 and 62.8 nM; 5-HT(1A)K(i)=14.2 and 0.82 nM, respectively).
Collapse
Affiliation(s)
- Roberto Perrone
- Dipartimento Farmaco-Chimico, Università degli Studi di Bari, via Orabona 4, 70125 Bari, Italy.
| | | | | | | | | | | | | |
Collapse
|
24
|
Becker I. Preparation of pyrimidine derivatives as potential medicinal agents by the reaction of 2-amino-4-chloro-6-methylpyrimidine with primary and secondary amines. J Heterocycl Chem 2005. [DOI: 10.1002/jhet.5570420707] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
25
|
Pinder RM. Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant? Neuropsychiatr Dis Treat 2005; 1:3-7. [PMID: 18568121 PMCID: PMC2426812 DOI: 10.2147/nedt.1.1.3.52293] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Noradrenaline has long played a key role in the way the etiology of depression is conceptualized and in the mechanism of action of many current antidepressants. Tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), selective noradrenaline reuptake inhibitors (NRIs), the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine, and many atypicals, like mianserin and bupropion, influence, at least in part, central noradrenergic function. Enhancement of noradrenergic function may be particularly helpful in patients with melancholia. However, while noradrenaline will continue to be a target for research into the etiology and treatment of depression, it is unlikely that antidepressants acting solely on noradrenaline will be pursued.
Collapse
Affiliation(s)
- Roger M Pinder
- Medical Affairs, CNS & Thrombosis, Organon International Inc, Oss The Netherlands.
| |
Collapse
|
26
|
Hieble JP, Ruffolo RR. Recent advances in the identification of a 1- and a 2-adrenoceptor subtypes: therapeutic implications. Expert Opin Investig Drugs 2005; 6:367-87. [PMID: 15989605 DOI: 10.1517/13543784.6.4.367] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The cloning of multiple subtypes of both alpha1- and alpha2-adrenoceptors has renewed interest in the therapeutic application of agents interacting with these receptors. Effort has primarily been directed towards the design of uroselective alpha1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia (BPH). Evidence is accumulating for the involvement of a novel alpha1-adrenoceptor, designated as alpha1L-adrenoceptor, in alpha1-adrenoceptor-mediated smooth muscle contraction in prostatic and other urogenital tissues. While several antagonists showing a high degree of uroselectivity in animal models have been identified, their clinical superiority over the currently available alpha1-adrenoceptor antagonists has not yet been demonstrated. It is possible that the interaction with alpha1-adrenoceptors, as yet uncharacterised subtypes, at non-prostatic sites contributes to the therapeutic activity of this drug class in BPH. The alpha1-adrenoceptor subtypes involved in the control of vascular tone are currently being evaluated, and the profile of interaction with the various alpha1-adrenoceptor subtypes may play a key role in the efficacy of cardiovascular drugs such as carvedilol. Alpha2-adrenoceptor agonists are now being employed for a variety of therapeutic applications, most involving actions on receptors within the central nervous system (CNS). These agents are useful in the treatment of hypertension, glaucoma, opiate withdrawal and attention deficit hyperactivity disorder (ADHD), and as analgesics and adjuncts to general anaesthesia. While subtype selectivity has not yet been applied to the design of new alpha2-adrenoceptor agonists for these applications, recent gene mutation/knock-out experiments have identified the alpha2-subtypes involved in some of these actions, and optimisation of a therapeutic profile may be possible. Furthermore, the design of agents combining affinities for multiple adrenoceptor subtypes, or the combination of a specific adrenoceptor affinity profile with another pharmacological action, may offer advantages over molecules selective for an individual adrenoceptor subtype.
Collapse
Affiliation(s)
- J P Hieble
- Division of Pharmacological Sciences, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406, USA
| | | |
Collapse
|
27
|
Pinder RM. Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant? Acta Neuropsychiatr 2004; 16:185-9. [PMID: 26984305 DOI: 10.1111/j.0924-2708.2004.00091.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Roger M Pinder
- 1Medical Affairs, Organon International Inc, Roseland, NJ, USA
| |
Collapse
|
28
|
Abstract
Both noradrenaline (NA) and serotonin (5-HT) appear to be involved in depression. Evidence suggests that dual-acting antidepressants, i.e. those that affect both monoamine systems, such as tricyclic antidepressants and the noradrenergic and specific serotonergic antidepressant mirtazapine, may have greater efficacy and a faster onset of action than drugs that act on a single monoamine system only, such as the selective serotonin reuptake inhibitors (SSRIs). Cell firing is reduced by SSRIs in the short-term, but is increased by mirtazapine, probably due to its actions on both NA (via alpha(2) antagonism) and 5-HT (via alpha(1)-stimulation by NA). This may help to explain clinical evidence suggesting that mirtazapine has a faster onset of action than the more selective antidepressants.
Collapse
Affiliation(s)
- Alan F Schatzberg
- Department of Psychiatry, Behavioral Sciences, Stanford University School of Medicine, Stanford, California 94305-5717, USA.
| |
Collapse
|
29
|
Ogier L, Turpin F, Baldwin RM, Riché F, Law H, Innis RB, Tamagnan G. Rearrangement of a mesylate tropane intermediate in nucleophilic substitution reactions. Synthesis of aza-bicyclo[3.2.1]octane and aza-bicyclo[3.2.2]nonane ethers, imides, and amines. J Org Chem 2002; 67:3637-42. [PMID: 12027674 DOI: 10.1021/jo010973x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Nucleophilic substitution of 2beta-mesyloxymethyl-N-methyl-3beta-p-tolyl-tropane intermediate with alkoxides, metal imides, or amines was found to lead not only to the expected bicyclo[3.2.1]octane (tropane) ether, imide, and amine derivatives but also to unexpected bicyclo[3.2.2]nonane derivatives. When alkoxides were used as nucleophile, only the rearranged bicyclo[3.2.2]nonane structure was obtained, whereas the use of amines or imides as nucleophile afforded a mixture of the two structures. The bicyclo[3.2.2]nonane structure was assigned by NMR analysis.
Collapse
Affiliation(s)
- Lionel Ogier
- Department of Psychiatry, Yale University and VA CT HCS, West Haven, Connecticut, USA
| | | | | | | | | | | | | |
Collapse
|
30
|
Clenet F, De Vos A, Bourin M. Involvement of 5-HT(2C) receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. Eur Neuropsychopharmacol 2001; 11:145-52. [PMID: 11313160 DOI: 10.1016/s0924-977x(01)00078-5] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Several recent studies have demonstrated that 5-HT(1A), 5-HT(1B) and 5-HT(3) receptors were implicated in the mechanism of action of antidepressants in the mouse forced swimming test. Despite extensive evidence for a role of 5-HT(2C) receptors in depression, the precise role of these receptors in the effects of clinically established antidepressants was not directly investigated in the mouse forced swimming test. This work was aimed at exploring interactions between several doses of Ro 60-0175, a recently available, full and selective 5-HT(2C) agonist, and antidepressant drugs in the mouse forced swimming test. Spontaneous locomotor activity was measured as an index of intact sensorimotor functions and the dose-effect of Ro 60-0175 alone, as well as interactions with several antidepressants, such as tricyclic antidepressants (imipramine, desipramine and maprotiline) and selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine, fluvoxamine and sertraline), were studied in the mouse forced swimming test. There was no intrinsic antidepressant-like effect of Ro 60-0175, but an impairment in locomotor function was detected when using doses higher than 4 mg/kg in the mouse. There was a synergistic effect of low doses of Ro 60-0175 with sub-active doses of imipramine, paroxetine, citalopram and fluvoxamine; an antagonism between the highest dose of Ro 60-0175 and the active doses of paroxetine and fluoxetine was also detected. There is evidence that 5-HT(2C) receptors may be involved in the action of antidepressants which are able to boost the concentration of serotonin in the synapse, i.e. SSRIs and imipramine
Collapse
Affiliation(s)
- F Clenet
- Faculté de Médecine et GIS Médicament, JE 2029 Neurobiologie de l'Anxieté, Faculté de Médecine, BP 53508, 1 rue Gaston Veil, F44035 Cedex 01, Nantes, France
| | | | | |
Collapse
|
31
|
Abstract
Modern antidepressants lack many of the side-effects and much of the toxicity of the first generation tricyclics and monoamine oxidase inhibitors. Knowledge of the receptor interactions that are responsible for poor tolerability and potential lethality in overdosage has enabled the design of agents that have low or no affinity for such receptors. Nevertheless, even the second generation selective serotonin reuptake inhibitors (SSRIs), the serotonin noradrenaline reuptake inhibitors (SNRIs) and the noradrenaline and serotonin specific antidepressants (NaSSAs) have not substantially improved upon the efficacy of the older agents. They still take some time to be effective, although venlafaxine and mirtazapine may be faster in onset than SSRIs, and they leave a substantial minority of patients unaffected.Innovative new antidepressants may be based upon a variety of mechanisms, including receptors, G-proteins, second messengers, gene transcription factors and the hypothalamic - pituitary - adrenal axis, but their availability may be hindered by recent advances in pharmaceutical research technology. Thus, the creation of large chemical libraries containing millions of new entities has increased structural diversity, but pharmacological evaluation has narrowed down to simple assays in high-throughput screening systems. Such assays depend to a major extent on how well they reflect the biological aetiology of the disease under study. While new antidepressant moieties will undoubtedly emerge, optimal use of the new research tools will necessitate a more sophisticated level of knowledge about the true causes of depression. Copyright 2001 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Roger M Pinder
- International Medical Director CNS & Cardiovascular, Organon Inc., 375 Mt. Pleasant Avenue, West Orange, NJ 07052, USA
| |
Collapse
|
32
|
Chung SH, Yook J, Min BJ, Lee JY, Lee YS, Jin C. Pharmacological characterization of (10bS)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline oxalate (YSL-3S) as a new alpha2-adrenoceptor antagonist. Arch Pharm Res 2000; 23:353-9. [PMID: 10976583 DOI: 10.1007/bf02975447] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Alpha2-adrenoceptor antagonists, which can enhance synaptic norepinephrine levels by blocking feedback inhibition processes, are potentially useful in the treatment of disease states such as depression, memory impairment, impotence and sexual dysfunction. (10bS)-1,2,3,5,6,10b-Hexahydropyrrolo[2,1-a]isoquinoline oxalate (YSL-3S) was evaluated in several in vitro biological tests to establish its pharmacological profile of activities as an alpha2-adrenoceptor antagonist. Saturation binding assay revealed that [3H]rauwolscine bound to the alpha2-adrenoceptors with a Kd value of 6.3+/-0.5 nM and a Bmax value of 251+/-39 fmol/mg protein in rat cortical synaptic membranes. Competitive binding assay showed that YSL-3S inhibited the binding of [3H]rauwolscine (1 nM) in a concentration-dependent manner with a Ki value of 98.2+/-12.1 nM while it did not inhibit the binding of [3H]cytisine (1.25 nM) to neuronal nicotinic cholinergic receptors. The Ki values of yohimbine, clonidine and norepinephrine for [3H]rauwolscine binding were 15.8+/-1.0, 40.1+/-5.9 and 40.0+/-11.5 nM, respectively. In addition, the binding affinity of YSL-3S for alpha2-adrenoceptors was higher than that of its antipode and the racemic mixture. The functional activity of YSL-3S at the presynaptic alpha2-adrenoceptors was assessed using the prostatic portion of the rat vas deferens. Clonidine inhibited field-stimulated contractions of the vas deference in a dose-dependent manner. The presence of YSL-3S or yohimbine caused a parallel, rightward the dose-response curve of clonidine in a dose-dependent manner, indicating an antagonistic action at the presynaptic alpha2-adrenoceptors. The pA2 values of yohimbine and YSL-3S were 7.66+/-0.13 and 6.64+/-0.18, respectively. The results indicate that YSL-3S acts as a competitive antagonist at presynaptic alpha2-adrenoceptors with a potency approximately ten times lower than yohimbine, but is devoid of binding affinity for neuronal nicotinic cholinergic receptors.
Collapse
Affiliation(s)
- S H Chung
- Bioanalysis & Biotransformation Research Center, Korea Institute of Science & Technology, Seoul
| | | | | | | | | | | |
Collapse
|
33
|
Millan MJ, Lejeune F, Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 2000; 14:114-38. [PMID: 10890307 DOI: 10.1177/026988110001400202] [Citation(s) in RCA: 166] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The frontal cortex (FCX) plays a key role in processes that control mood, cognition and motor behaviour, functions which are compromised in depression, schizophrenia and other psychiatric disorders. In this regard, there is considerable evidence that a perturbation of monoaminergic input to the FCX is involved in the pathogenesis of these states. Correspondingly, the modulation of monoaminergic transmission in the FCX and other corticolimbic structures plays an important role in the actions of antipsychotic and antidepressant agents. In order to further understand the significance of monoaminergic systems in psychiatric disorders and their treatment, it is essential to characterize mechanisms underlying their modulation. Within this framework, the present commentary focuses on our electrophysiological and dialysis analyses of the complex and reciprocal pattern of auto- and heteroreceptor mediated control of dopaminergic, noradrenergic and serotonergic transmission in the FCX. The delineation of such interactions provides a framework for an interpretation of the influence of diverse classes of antidepressant agent upon extracellular levels of dopamine, noradrenaline and serotonin in FCX. Moreover, it also generates important insights into strategies for the potential improvement in the therapeutic profiles of antidepressant agents.
Collapse
Affiliation(s)
- M J Millan
- Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, Croissy-sur-Seine, France
| | | | | |
Collapse
|
34
|
Oficialdegui AM, Martinez J, Pérez S, Heras B, Irurzun M, Palop JA, Tordera R, Lasheras B, del Río J, Monge A. Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual mode of action: serotonin reuptake inhibition and 5-HT1A receptor antagonism. FARMACO (SOCIETA CHIMICA ITALIANA : 1989) 2000; 55:345-53. [PMID: 10983279 DOI: 10.1016/s0014-827x(00)00050-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
It has been suggested that the combination of a selective serotonin reuptake inhibitor (SSRI) and a 5-HT1A receptor antagonist may facilitate the onset of the SSRIs antidepressant action. Accordingly, we describe the synthesis of a series of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives with structural modifications performed in Ar1, Ar2 and Z (Z is different functional groups) to obtain the sought dual activity. Compounds were evaluated for in vitro affinity at 5-HT1A receptors and 5-HT transporter. The antidepressant-like activity of derivatives with the higher affinity was assessed initially using the forced swimming test (FST). Compound 1-(2,4-dimethylphenyl)-3-[(2-methoxyphenyl)piperazin-1-il]-1-propa none (III.1.a) showed the best antidepressant-like activity which was further confirmed in the learned helplessness test.
Collapse
Affiliation(s)
- A M Oficialdegui
- Department of Medicinal Chemistry, Universidad de Navarra, Pamplona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Li LB, Reith ME. Interaction of Na+, K+, and Cl- with the binding of amphetamine, octopamine, and tyramine to the human dopamine transporter. J Neurochem 2000; 74:1538-52. [PMID: 10737611 DOI: 10.1046/j.1471-4159.2000.0741538.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Little information is available on the role of Na+, K+, and Cl- in the initial event of uptake of substrates by the dopamine transporter, i.e., the recognition step. In this study, substrate recognition was studied via the inhibition of binding of [3H]WIN 35,428 [2beta-carbomethoxy-3beta-(4-fluorophenyl)[3H]tropane], a cocaine analogue, to the human dopamine transporter in human embryonic kidney 293 cells. D-Amphetamine was the most potent inhibitor, followed by p-tyramine and, finally, dl-octopamine; respective affinities at 150 mM Na+ and 140 mM Cl- were 5.5, 26, and 220 microM. For each substrate, the decrease in the affinity with increasing [K+] could be fitted to a competitive model involving the same inhibitory cation site (site 1) overlapping with the substrate domain as reported by us previously for dopamine. K+ binds to this site with an apparent affinity, averaged across substrates, of 9, 24, 66, 99, and 134 mM at 2, 10, 60, 150, and 300 mM Na+, respectively. In general, increasing [Na+] attenuated the inhibitory effect of K+ in a manner that deviated from linearity, which could be modeled by a distal site for Na+, linked to site 1 by negative allosterism. The presence of Cl- did not affect the binding of K+ to site 1. Models assuming low binding of substrate in the absence of Na+ did not provide fits as good as models in which substrate binds in the absence of Na+ with appreciable affinity. The binding of dl-octopamine and p-tyramine was strongly inhibited by Na+, and stimulated by Cl- only at high [Na+] (300 mM), consonant with a stimulatory action of Cl- occurring through Na+ disinhibition.
Collapse
Affiliation(s)
- L B Li
- Department of Biology, Illinois State University, Normal, USA
| | | |
Collapse
|
36
|
Tamiz AP, Smith MP, Kozikowski AP. Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine. Bioorg Med Chem Lett 2000; 10:297-300. [PMID: 10698458 DOI: 10.1016/s0960-894x(99)00685-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The synthesis and biological activity of a series of azatricyclodecane analogues of cocaine are described. All compounds studied in this series exhibit nanomolar potency and good selectivity for the serotonin transporter versus the dopamine transporter.
Collapse
Affiliation(s)
- A P Tamiz
- Drug Discovery Program, Institute of Cognitive and Comuputational Science, Georgetown University Medical Center, Washington, DC 20007-2197, USA
| | | | | |
Collapse
|
37
|
Oshiro Y, Sakurai Y, Sato S, Kurahashi N, Tanaka T, Kikuchi T, Tottori K, Uwahodo Y, Miwa T, Nishi T. 3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives. J Med Chem 2000; 43:177-89. [PMID: 10649973 DOI: 10.1021/jm980333v] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
To develop a novel antidepressant drug with central nervous system-stimulating activity, we prepared a series of 1-[omega-(4-substituted phenyl-1-piperazinyl)alkyl]-3, 4-dihydro-2(1H)-quinolinone derivatives and examined their activities by their effects at 30 and 100 mg/kg po on the sleeping time of mice anesthetized with halothane and on the time required for recovery from coma induced in mice by cerebral concussion. We examined their binding affinities for sigma receptors by evaluating their ability to inhibit [(3)H]-1,3-di(o-tolyl)guanidine ([(3)H]DTG) binding to the rat whole brain membrane in comparison with three putative sigma receptor agonists: 1,3-di(o-tolyl)guanidine (DTG, 66), (+)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(2-propenyl)-2, 6-methano-3-benzazecin-8-ol (SKF10,047, 67), and (+)-1,2,3,4,5, 6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2, 6-methano-3-benzazecin-8-ol (pentazocine, 68). Among the series of derivatives, 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3, 4-dihydro-5-methoxy-2(1H)-quinolinone hydrochloride (34b) and its mesylate (34c), at a dose of 30 mg/kg po, reduced the sleeping time and the time for recovery from coma and they inhibited [(3)H]DTG binding for sigma receptors. The putative sigma receptor agonists reduced the sleeping time and the time for recovery from coma whereas two sigma receptor antagonists, alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride (BMY14802, 69) and cis-9-[3-(3, 5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride (rimcazole, 70), were inactive in the two tests. Preadministration of the putative sigma receptor antagonists 69 (3 mg/kg po) and 70 (30 mg/kg po) completely antagonized the actions of 34b and the sigma receptor agonists in the test for recovery from coma. These results suggested that 34b and 34c are sigma receptor agonists. Furthermore, a single administration of 1 and 10 mg/kg po 34b and 34c showed antidepressant-like activity by reducing the immobility time in the forced-swimming test with mice, while a tricyclic antidepressant, 10, 11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine hydrochloride (imipramine, 1) (10 and 30 mg/kg po), did not reduce the time after a single administration. 1 reduced the time after repeated administration of 30 mg/kg po once a day for 4 days. The structure-activity relationship of the series of compounds is also discussed.
Collapse
Affiliation(s)
- Y Oshiro
- Otsuka Pharmaceutical Company Ltd., Third Tokushima Institute of New Drug Research, 463-10 Kagasuno, Kawauchi-cho, Tokushima 771-0192, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Sánchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19:467-89. [PMID: 10379421 DOI: 10.1023/a:1006986824213] [Citation(s) in RCA: 324] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
1. The present survey compares the effects of antidepressants and their principal metabolites on reuptake of biogenic amines and on receptor binding. The following antide-pressants were included in the study: the tricyclic antidepressants amitriptyline, dothiepin, and lofepramine and the atypical antidepressant bupropion, which all have considerable market shares in the UK and/or US markets; the selective serotonin reuptake inhibitors (SSRIs) citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline; and the recently approved antidepressants venlafaxine and nefazodone. 2. Amitriptyline has similar in vitro reuptake inhibitory potencies for 5-HT and NA, whereas the metabolite nortriptyline is preferentially a NA reuptake inhibitor. Both amitriptyline and nortriptyline are also 5-HT2 receptor antagonists. 3. Dothiepin has equipotent 5-HT and NA reuptake inhibitory activity, whereas northiaden shows a slight selectivity for NA reuptake inhibition. Dothiepin and northiaden are also 5-HT2 receptor antagonists. The slow elimination rate of northiaden (36-46 hr) compared to dothiepin (14-24 hr) suggests that northiaden contributes significantly to the therapeutic effect of dothiepin. 4. Lofepramine is extensively metabolized to desipramine. Desipramine plays an important role in the antidepressant activity of lofepramine, as the plasma elimination half-life of lofepramine (4-6 hr) is much shorter than that of desipramine (24 hr). Both compounds are potent and selective inhibitors of NA reuptake. 5. The five approved SSRIs, citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, are potent 5-HT reuptake inhibitors, and the demethyl metabolites, norfluoxetine, demethylsertraline, and demethylcitalopram, also show selectivity. Paroxetine and sertraline are the most potent inhibitors of 5-HT reuptake, whereas citalopram is the most selective. Fluoxetine is the least selective and the metabolite of fluoxetine, norfluoxetine, is a more selective and more potent 5-HT reuptake inhibitor than the parent compound and has an extremely long half-life (7-15 compared to 1-3 days). Thus the metabolite plays an important role for the therapeutic effect of fluoxetine. Fluoxetine is also a 5-HT2C receptor antagonist. Demethylsertraline is a weaker and less selective 5-HT reuptake inhibitor in vitro than sertraline, but demethylsertraline has a very long half-life (62-104 hr) compared to the parent compound (24 hr) and it might play a role in the therapeutic effects of sertraline. Demethylcitalopram has about a 10 times lower 5-HT reuptake inhibitory potency in vitro than citalopram, and the elimination half-lives are approximately 1.5 and 2 days, respectively. 6. Bupropion and hydroxybupropion are weak inhibitors of biogenic amine reuptake. The mechanisms of action responsible for the clinical effects of bupropion are not fully understood, but it has been suggested that both dopaminergic and noradrenergic components play a role and that the hydroxybupropion metabolite contributes significantly to the antidepressant activity. 7. Venlafaxine and O-demethylvenlafaxine are weak inhibitors of 5-HT and NA reuptake, and the selectivity ratios are close to one. O-Demethylvenlafaxine is eliminated more slowly than venlafaxine (plasma half-lives of 5 and 11 hr, respectively), and it is likely that it contributes to the overall therapeutic effect of venlafaxin. 8. Nefazodone and alpha-hydroxynefazodone are equipotent 5-HT and NA reuptake inhibitors. Both compounds are also 5-HT2 receptor antagonists. Both parent compound and metabolite have short elimination half-lives.
Collapse
MESH Headings
- Animals
- Antidepressive Agents/metabolism
- Antidepressive Agents/pharmacology
- Antidepressive Agents/therapeutic use
- Antidepressive Agents, Second-Generation/metabolism
- Antidepressive Agents, Second-Generation/pharmacology
- Antidepressive Agents, Second-Generation/therapeutic use
- Antidepressive Agents, Tricyclic/metabolism
- Antidepressive Agents, Tricyclic/pharmacokinetics
- Binding, Competitive/drug effects
- Biogenic Amines/metabolism
- Depression/drug therapy
- Depression/metabolism
- Humans
- Receptors, Catecholamine/drug effects
- Receptors, Catecholamine/metabolism
- Receptors, Serotonin/drug effects
- Receptors, Serotonin/metabolism
- Selective Serotonin Reuptake Inhibitors/metabolism
- Selective Serotonin Reuptake Inhibitors/pharmacology
- Selective Serotonin Reuptake Inhibitors/therapeutic use
Collapse
|
39
|
Lee CH, Oh JI, Park HD, Kim HJ, Park TK, Kim JS, Hong CY, Lee SJ, Ahn KH, Kim YZ. Pharmacological characterization of LB50016, N-(4-amino)butyl 3-phenylpyrrolidine derivative, as a new 5-HT1A receptor agonist. Arch Pharm Res 1999; 22:157-64. [PMID: 10230506 DOI: 10.1007/bf02976540] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
LB50016 was characterized as a selective and potent 5-HT1A receptor agonist and evaluate its anxiolytic and antidepressant activities. It shows high affinity for 5-HT1A receptor, moderate affinity for alpha 2 adrenergic and 5-HT2A receptors and no significant affinity for other receptors tested. Hypothermia and increased serum corticosterone level were observed in LB50016-treated rats, which are mediated mostly by post synaptic 5-HT1A receptor activation. In the mouse forced swim model for depression, LB50016-elicited dose-dependent reductions in immobility time, showing ED50 of approximately 3 mg/kg i.p., which was blocked by pretreatment of NAN-190, 5-HT1A antagonist. In face-to-face test for anxiolytic activity in mice, estimated ED50 was 2 mg/kg, i.p. In isolation-induced aggression test with mice, fifty-fold increases in latency to attack were observed at 30 min and last up to 4 h after LB50016 treatment (3 mg/kg, i.p.). Taken together, LB50016-induced pharmacological activities are mediated by activation of 5-HT1A receptors, offering an effective therapeutic candidate in the management of anxiety and depression in humans.
Collapse
Affiliation(s)
- C H Lee
- Department of Pharmacology, Hanyang University, College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Vizi ES, Kiss JP. Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions. Hippocampus 1999; 8:566-607. [PMID: 9882017 DOI: 10.1002/(sici)1098-1063(1998)8:6<566::aid-hipo2>3.0.co;2-w] [Citation(s) in RCA: 278] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Hippocampus plays a crucial role in important brain functions (e.g. memory, learning) thus in the past two decades this brain region became a major objective of neuroscience research. During this period large number of anatomical, neurochemical and electrophysiological data have been accumulated. While excellent reviews have been published on the anatomy and electrophysiology of hippocampal formation, the neurochemistry of this area has not been thoroughly surveyed. Therefore the aim of this review is to summarize the neurochemical and pharmacological data on the release of the major neurotransmitters found in the hippocampal region: glutamate (GLU), gamma-amino butyric acid (GABA), acetylcholine (ACh), noradrenaline (NA) and serotonin (5-HT). In addition, this review analyzes the synaptic and nonsynaptic interactions between hippocampal neuronal elements and overviews how auto- and heteroreceptors are involved in the presynaptic modulation of transmitter release. The presented data clearly show that transmitters released from axon terminals without synaptic contact play an important role in the fine tuning of communication between neurons within a neuronal circuit.
Collapse
Affiliation(s)
- E S Vizi
- Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest.
| | | |
Collapse
|
41
|
Haddjeri N, Blier P, de Montigny C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 1998; 51:255-66. [PMID: 10333981 DOI: 10.1016/s0165-0327(98)00223-7] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Mirtazapine (ORG 3770, Remeron) is a new alpha 2-adrenoceptor antagonist which has been shown to be an effective antidepressant drug. The aims of the studies were to assess, using an in vivo electrophysiological paradigm in the rat, the effects of acute and long-term treatment with mirtazapine on pre- and postsynaptic alpha 2-adrenoceptors and to determine whether this drug could modulate serotonin (5-HT) neurotransmission. Acute administration of mirtazapine produced a transient increase of the firing activity of dorsal raphe 5-HT neurons. This effect was mediated via norepinephrine (NE) neurons because it was abolished in NE-lesioned rats. In fact, this increased firing rate of 5-HT neurons was due to their activation by the enhanced release of NE resulting from the blockade of alpha 2-adrenergic autoreceptors of locus coeruleus neurons. Furthermore, acute mirtazapine injection transiently enhanced the firing activity of locus coeruleus NE neurons and attenuated the suppressant effect of the alpha 2-adrenoceptor agonist clonidine on these NE neurons. Sustained administration of mirtazapine for 21 days (5 mg/kg/day, s.c., using minipumps) lead to a marked increase in the firing rate of 5-HT neurons (75%) but a more modest increase in the firing rate of NE neurons (30%), as well as to a desensitization of alpha 2-adrenergic heteroreceptors on 5-HT terminals in the hippocampus. The desensitization of these heteroreceptors, resulting from an increased synaptic availability of NE induced by mirtazapine would free 5-HT terminals from the inhibitory influence of NE on 5-HT release. These modifications of 5-HT neurons lead to an increased tonic activation of postsynaptic 5-HT1A receptors. The latter conclusion was based on the capacity of the selective 5-HT1A receptor antagonist WAY 100635 to enhance the firing activity of dorsal hippocampus CA3 pyramidal neurons in mirtazapine-treated rats but not in controls. This enhanced 5-HT neurotransmission may underlie to the antidepressant effect of mirtazapine.
Collapse
Affiliation(s)
- N Haddjeri
- Department of Psychiatry, McGill University, Montréal, Québec, Canada
| | | | | |
Collapse
|
42
|
Gaster LM, Blaney FE, Davies S, Duckworth DM, Ham P, Jenkins S, Jennings AJ, Joiner GF, King FD, Mulholland KR, Wyman PA, Hagan JJ, Hatcher J, Jones BJ, Middlemiss DN, Price GW, Riley G, Roberts C, Routledge C, Selkirk J, Slade PD. The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem 1998; 41:1218-35. [PMID: 9548813 DOI: 10.1021/jm970457s] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
5-HT1 receptors are members of the G-protein-coupled receptor superfamily and are negatively linked to adenylyl cyclase activity. The human 5-HT1B and 5-HT1D receptors (previously known as 5-HT1Dbeta and 5-HT1Dalpha, respectively), although encoded by two distinct genes, are structurally very similar. Pharmacologically, these two receptors have been differentiated using nonselective chemical tools such as ketanserin and ritanserin, but the absence of truly selective agents has meant that the precise function of the 5-HT1B and 5-HT1D receptors has not been defined. In this paper we describe how, using computational chemistry models as a guide, the nonselective 5-HT1B/5-HT1D receptor antagonist 4 was structurally modified to produce the selective 5-HT1B receptor inverse agonist 5, 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6, 7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289). This compound is a potent antagonist of terminal 5-HT autoreceptor function both in vitro and in vivo.
Collapse
Affiliation(s)
- L M Gaster
- SmithKline Beecham Pharmaceuticals, Discovery Research, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, England
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Carlier PR, Lo MM, Lo PC, Richelson E, Tatsumi M, Reynolds IJ, Sharma TA. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg Med Chem Lett 1998; 8:487-92. [PMID: 9871604 DOI: 10.1016/s0960-894x(98)00062-6] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A series of gamma-amino alcohols were synthesized and screened for reuptake inhibition and noncompetitive NMDA antagonism. Compound (+/-)-3f simultaneously and potently inhibits reuptake of 5-HT, NE, and DA, representing a potential wide-spectrum reuptake inhibitor antidepressant. In addition, comparative rat and human studies uncovered a species-selective DA reuptake inhibitor (+/-)-2e, KD(hDAT)/KD(rDAT) = 97.
Collapse
Affiliation(s)
- P R Carlier
- Department of Chemistry, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong
| | | | | | | | | | | | | |
Collapse
|
44
|
Nishiyama M, Yamamoto T, Koie Y. Synthesis of N-arylpiperazines from aryl halides and piperazine under a palladium tri-tert-butylphosphine catalyst. Tetrahedron Lett 1998. [DOI: 10.1016/s0040-4039(97)10659-1] [Citation(s) in RCA: 257] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
|
46
|
He H, Richardson JS. Nefazodone: A Review of Its Neurochemical Mechanisms, Pharmacokinetics, and Therapeutic Use in Major Depressive Disorder. CNS DRUG REVIEWS 1997. [DOI: 10.1111/j.1527-3458.1997.tb00315.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Abstract
Although longer-term adaptive changes in receptor sensitivity may better explain the delayed onset of action of antidepressants, the mechanism based on acutely elevated noradrenaline (NA) and serotonin (5-HT) synaptic levels remains the basis for new drug design. The dual action concept, which postulates that effects on both NA and 5-HT are more advantageous than a selective action on serotonin reuptake (SSRI), has been used to design new antidepressants such as venlafaxine and mirtazapine. Both drugs enhance NA and 5-HT neurotransmission with little affinity for receptors mediating tricyclic-like side effects. Mirtazapine, the prototype noradrenergic and specific serotonergic antidepressant (NaSSA), specifically enhances 5-HT1 neurotransmission and blocks 5-HT2 and 5-HT3 receptors, and in contrast to venlafaxine lacks SSRI-like and adverse cardiovascular side effects. The unique pharmacological action of mirtazapine is a result of implementation of two concepts: dual action as a basis of efficacy combined with receptor-specific action as a basis of tolerability.
Collapse
|
48
|
5-HT transporter. ACTA ACUST UNITED AC 1997. [DOI: 10.1016/s0165-7208(97)80019-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/13/2023]
|
49
|
Díaz JA, Vega S, Expósito MA, Sánchez Mateo CC, Darias V. Synthesis and antidepressant evaluation of new hetero[2,1]benzothiazepine derivatives. Arch Pharm (Weinheim) 1996; 329:352-60. [PMID: 8764884 DOI: 10.1002/ardp.19963290705] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
As a part of a research program directed to the discovery of novel antidepressant agents, a series of new hetero[2,1]benzothiazepine derivatives was synthesized. Some of these compounds antagonized the ptosis and motor depression induced by tetrabenazine and were also active in the Porsolt forced swimming test.
Collapse
Affiliation(s)
- J A Díaz
- Instituto de Química Médica, CSIC, Madrid, Spain
| | | | | | | | | |
Collapse
|
50
|
Gardier AM, Malagié I, Trillat AC, Jacquot C, Artigas F. Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 1996; 10:16-27. [PMID: 8900496 DOI: 10.1111/j.1472-8206.1996.tb00145.x] [Citation(s) in RCA: 161] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Although a new generation of selective serotonin reuptake inhibitors (SSRIs) has been introduced in therapeutics as antidepressant drugs, a two to four week lag period still occurs between starting treatment with SSRIs and the onset of therapeutic effects in man. In vivo cerebral microdialysis can be used to measure extracellular concentrations of serotonin (5-hydroxytryptamine, 5-HT), which reflect intrasynaptic events. With the coupling of this new experimental method to very sensitive analytical assays such as liquid chromatography with electrochemical detection, it has recently been possible to obtain two major arguments supporting the hypothesis that somatodendritic 5-HT1A autoreceptors situated in the raphe nuclei play an important role in the mechanism of action of SSRIs. First, in the rat, single administration of SSRIs at low doses comparable to those used therapeutically increases extracellular 5-HT concentrations in the vicinity of the cell body and the dendrites of serotoninergic neurones of the raphe nuclei. This effect is more marked than that observed in regions rich in nerve endings (frontal cortex). The magnitude of the activation of the serotoninergic neurotransmission depends on the brain area studied and the dose of the SSRIs administered to rats. This could be explained by simultaneous activation of somatodendritic 5-HT1A autoreceptors by endogenous 5-HT in the raphe nuclei, thereby limiting the corticofrontal effects of the antidepressant. Second, SSRIs cause a larger increase in extracellular 5-HT concentrations in the nerve endings when administered chronically: 5-HT autoreceptors may have gradually desensitized during the 2-4 weeks of treatment with SSRIs. Preliminary studies of patients with depression appear to confirm these experimental results, as co-administration of a 5-HT1A autoreceptor antagonist and a SSRI accelerated the onset of the antidepressant effect (< 1 week).
Collapse
Affiliation(s)
- A M Gardier
- Faculté de Pharmacie, Université Paris-Sud, Chatenay-Malabry, France
| | | | | | | | | |
Collapse
|